News
-
-
-
PRESS RELEASE
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
Valorum Biologics LLC partners with Formycon AG for commercialization of Eylea biosimilar FYB203/AHZANTIVE in the United States and Canada. Major shareholder ATHOS KG supports financing -
-
-
-
-
-
-